These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 22411844)
1. Is executive control used to compensate for involuntary movements in levodopa-induced dyskinesia? Aron AR; Obeso J Mov Disord; 2012 Mar; 27(3):339-40. PubMed ID: 22411844 [No Abstract] [Full Text] [Related]
2. Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task. Cerasa A; Pugliese P; Messina D; Morelli M; Gioia MC; Salsone M; Novellino F; Nicoletti G; Arabia G; Quattrone A Mov Disord; 2012 Mar; 27(3):364-71. PubMed ID: 22076870 [TBL] [Abstract][Full Text] [Related]
3. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Bezard E; Brotchie JM; Gross CE Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001 [TBL] [Abstract][Full Text] [Related]
4. Increased prefrontal volume in PD with levodopa-induced dyskinesias: a voxel-based morphometry study. Cerasa A; Messina D; Pugliese P; Morelli M; Lanza P; Salsone M; Novellino F; Nicoletti G; Arabia G; Quattrone A Mov Disord; 2011 Apr; 26(5):807-12. PubMed ID: 21384430 [TBL] [Abstract][Full Text] [Related]
6. Direct and indirect pathways in levodopa-induced dyskinesia: a more complex matter than a network imbalance. Ghiglieri V; Picconi B; Calabresi P Mov Disord; 2010 Aug; 25(11):1527-9. PubMed ID: 20623774 [No Abstract] [Full Text] [Related]
11. The acute brain response to levodopa heralds dyskinesias in Parkinson disease. Herz DM; Haagensen BN; Christensen MS; Madsen KH; Rowe JB; Løkkegaard A; Siebner HR Ann Neurol; 2014 Jun; 75(6):829-36. PubMed ID: 24889498 [TBL] [Abstract][Full Text] [Related]
12. Levodopa-induced morphologic changes of prefrontal pyramidal tract-type neurons in a rat model of Parkinson's disease. Nishijima H; Ueno T; Ueno S; Mori F; Miki Y; Tomiyama M Neurosci Res; 2017 Feb; 115():54-58. PubMed ID: 27773835 [TBL] [Abstract][Full Text] [Related]
13. Clinical spectrum of levodopa-induced complications. Aquino CC; Fox SH Mov Disord; 2015 Jan; 30(1):80-9. PubMed ID: 25488260 [TBL] [Abstract][Full Text] [Related]
14. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease. LeWitt PA Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783 [TBL] [Abstract][Full Text] [Related]
16. Worsening of levodopa-induced dyskinesias by motor and mental tasks. Durif F; Vidailhet M; Debilly B; Agid Y Mov Disord; 1999 Mar; 14(2):242-5. PubMed ID: 10091616 [TBL] [Abstract][Full Text] [Related]
17. [Long-term complications of treatment with levodopa]. Castro García A; Sesar Ignacio A Neurologia; 1998; 13 Suppl 1():41-8. PubMed ID: 9859685 [No Abstract] [Full Text] [Related]
18. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease. Tousi B; Subramanian T Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966 [No Abstract] [Full Text] [Related]
19. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease. Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615 [TBL] [Abstract][Full Text] [Related]
20. What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias. Kordower JH Mov Disord; 2017 Apr; 32(4):483-484. PubMed ID: 28425143 [No Abstract] [Full Text] [Related] [Next] [New Search]